Insights
Search Results
Client Highlights
4.27.26
Wilson Sonsini Advises Nervonik on $52.5 Million Series B Financing
On April 27, 2026, Nervonik, a clinical-stage medical device company developing next-generation peripheral nerve stimulation (PNS) technologies, announced the closing of an oversubscribed $52.5 million Series B financing. The round was led by Amzak Health, with participation from Elevage Medical Technologies, U.S. Venture Partners (USVP), Lumira Ventures, Foothill Ventures, and Shangbay Capital. The proceeds from the financing will support the continued development and commercialization of Nervonik's PNS system, including further development of its proprietary sensing capabilities. Wilson Sonsini Goodrich & Rosati advised Nervonik on the transaction.
Client Highlights
4.02.26
Wilson Sonsini Advises View Point Medical on Acquisition by Merit Medical
On April 1, 2026, Merit Medical Systems, Inc., a global leader of healthcare technology, announced it has acquired View Point Medical, Inc. The aggregate transaction consideration, including the assumption of View Point liabilities, is approximately $140 million. Wilson Sonsini Goodrich & Rosati advised View Point on the transaction.
Client Highlights
3.31.26
Wilson Sonsini Advises Insilico on Global R&D Collaboration with Lilly
On March 29, 2026, Insilico Medicine (Insilico), a clinical-stage biotechnology company powered by generative artificial intelligence (AI) and automation, announced a drug discovery collaboration with Eli Lilly and Company (Lilly) that uses Insilico's AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
Client Highlights
3.25.26
Wilson Sonsini Advises Nosis Bio on Strategic Collaboration and License Agreement with Johnson & Johnson
On March 24, 2026, Nosis Bio, a pioneer in AI-enabled cell-specific delivery for RNA medicines, announced an expansion of its strategic collaboration with Johnson & Johnson. Their initial collaboration has been expanded through an option exercise, and simultaneously, Nosis Bio and Johnson & Johnson have entered into a new strategic collaboration agreement focused on neurology. The collaborations will deploy Nosis’ Connexa™ platform, which combines a proprietary atlas of cell-specific internalizing receptor targets with physics-aware generative AI, to design delivery vehicles that can navigate complex cell types. Wilson Sonsini Goodrich & Rosati advised Nosis Bio on the transaction.
Client Highlights
11.13.25
Wilson Sonsini Advises Insilico on Research and Licensing Collaboration with Lilly
On November 10, 2025, Insilico Medicine (Insilico), a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced a research collaboration with Eli Lilly (Lilly) where the two parties will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies. Wilson Sonsini Goodrich & Rosati advised Insilico on the transaction.
News Articles
10.01.25
LMG Life Sciences Recognizes Wilson Sonsini, Attorneys in 2025 Guide
On September 30, 2025, LMG Life Sciences announced the 2025 edition of its guide, which identifies and ranks the leading law firms and individuals in the life sciences industry across the United States. The rankings are the result of firm participation in questionnaires, partner interviews to gather market feedback, client surveys, and independent research. LMG Life Sciences has conducted research and published rankings since 2012. This year, six Wilson Sonsini practices and 18 attorneys have been recognized in the guide.
News Articles
9.05.25
Wilson Sonsini Honored During 2025 LMG Life Sciences Awards
On September 4, 2025, Wilson Sonsini was named Licensing and Collaboration Firm of the Year winner during the 2025 LMG Life Sciences Awards, an annual awards program that honors the top firms and legal professionals in the life sciences sector. The firm had also been a finalist in two additional categories: Hatch-Waxman Litigation Firm of the Year (Generic) and Venture Capital Firm of the Year.
Client Highlights
5.21.25
Wilson Sonsini Advises Halo Labs on Acquisition by Waters
On May 21, 2025, Waters Corporation announced that it acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. Wilson Sonsini Goodrich & Rosati advised Halo Labs on the transaction.
Client Highlights
1.13.25
Wilson Sonsini Advises Bolt Medical on Merger with Boston Scientific
On January 8, 2025, Boston Scientific announced it has entered into a definitive agreement to acquire Bolt Medical, the developer of an intravascular lithotripsy (IVL) advanced laser-based platform for the treatment of coronary and peripheral artery disease, for up to $900 million. Wilson Sonsini Goodrich & Rosati advised Bolt Medical on the transaction.
Client Highlights
12.23.24
Wilson Sonsini Advises USANA Health Sciences on Acquisition of Hiya Health
On December 23, 2024, USANA Health Sciences announced the acquisition of a 78.8 percent controlling ownership stake in Hiya Health Products, a leading direct-to-consumer provider of high-quality children’s health and wellness products. The $205 million cash transaction was completed on the same date and is anticipated to be accretive to USANA’s 2025 adjusted EBITDA. Wilson Sonsini Goodrich & Rosati advised USANA on the transaction.
Client Highlights
11.14.24
Wilson Sonsini Advises LaNova Medicines on Exclusive Global License with Merck
On November 14, 2024, Merck and LaNova Medicines, a privately held clinical-stage biotechnology company, announced that they entered into an exclusive global license for Merck to develop, manufacture, and commercialize LM-299, a novel investigational bispecific antibody targeting both programmed cell death protein-1 (PD-1) and vascular endothelial growth factor (VEGF) that is currently in Phase 1 clinical trials in China. Wilson Sonsini Goodrich & Rosati advised LaNova on the transaction.
Client Highlights
10.09.24
Wilson Sonsini Advises Circle Pharma on Research Collaboration with Boehringer Ingelheim
On October 9, 2024, Circle Pharma (Circle), a clinical-stage biopharmaceutical company dedicated to discovering and developing cell-permeable macrocycles as a new class of therapies, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, announced a new research collaboration and licensing agreement with a shared objective to create a pioneering cyclin inhibitor. This innovative development could potentially halt the growth of cancer cells in patients living with hard-to-treat cancers. Wilson Sonsini advised Circle on the transaction.